Becton Dickinson and Co (BDX) FinancialsBDXBecton Dickinson and Co

Becton Dickinson and Co (BDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medication Delivery Solutions, accounting for 23.4% of total sales, equivalent to $1.16B. Other significant revenue streams include Medication Management Solutions and Surgery. Understanding this composition is critical for investors evaluating how BDX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Becton Dickinson and Co maintains a gross margin of 46.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.28%, while the net margin is 9.05%. These profitability ratios, combined with a Return on Equity (ROE) of 6.61%, provide a clear picture of how effectively BDX converts its operational activities into shareholder value.

In the context of the broader market, BDX competes directly with industry leaders such as EW and A. With a market capitalization of $51.04B, it holds a leading position in the sector. When comparing efficiency, BDX's gross margin of 46.76% stands against EW's 77.46% and A's 55.54%. Such benchmarking helps identify whether Becton Dickinson and Co is trading at a premium or discount relative to its financial performance.

Becton Dickinson has shown a gross margin of 46.76% in Q3 2026, with a recent net income of 377 million USD, reflecting a recovery from the previous quarter's loss. Total revenue for Q3 2026 was 4.983 billion USD, indicating stable performance despite recent challenges.